The Global Non-Small Cell Lung Carcinoma (NSCLC) Market is on the brink of an extraordinary transformation, with market ...

SALES FORECAST: The Swiss pharma giant's third-quarter sales are forecast at 14.89 billion Swiss francs ($17.22 billion), according to a consensus of 11 analysts' estimates compiled by Visible Alpha.

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Roche Holding AG (RHHVF – Research ...

U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

Cathie Wood, the CEO of Ark Invest, has several AI stocks in her investment management firm's actively managed ETFs. One of ...

USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in treatment. However, this October brings ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

A smart beta exchange traded fund, the Hartford Multifactor Developed Markets (ex-US) ETF (RODM) debuted on 02/25/2015, and offers broad exposure to the Broad Developed World ETFs category of the ...

Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...